P
P
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
2
$33.69M
Total Volume
$33.69M
2 transactions
Net Activity
$33.69M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
No Recent Signal
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
P has an insider buy conviction of 0%, compared to the Unknown sector buy average of 50%.
Colgrove John
Chief Visionary Officer
$33.69M total
Over the last 90 days, corporate insiders at P (P) engaged in a total of 2 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 2 were sales. The total volume of insider trading reached $33.69M.
The net insider activity for P shows a net selling bias of $33.69M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Colgrove John (Chief Visionary Officer), who traded 200.0K shares valued at $22.65M on Sep 22, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering P and the Unknown sector.
The AI Circular Valuation Bubble: Inside the Venture-Cloud Loop
An in-depth investigation into how technology giants and AI startups engage in circular capital flows, investing venture capital in exchange for cloud services and hardware, creating a closed-loop economy that artificially inflates valuations.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
The Spinoff Separation: Tracking Post-Spinoff Executive Ownership Trends
An investigation of corporate spinoffs, showing how executive equity allocations and post-separation insider transactions signal parent and subsidiary performance trajectories.
The Lockup Expiration Wave: Venture Capital Post-IPO Exit Strategies
A data-driven analysis of how venture capital firms and pre-IPO insiders manage lockup expirations, detailing block trade execution, distribution methods, and stock price impact.
Lock-up Expiration Frontrunning: How Venture Funds Manage Large Block Trades
When lock-up periods expire, venture funds use block trades, 10b-18 programs, and coordinated secondary offerings to exit large positions. This report reveals the strategies that minimize price impact, and how retail investors can track them.
Deciphering Form 5 Filings: Uncovering Annual Insider Gift Trades
A comprehensive guide to SEC Form 5 filings, explaining how annual reports of gift shares, stock options, and non-open-market transactions signal insider sentiment.
FAQs About P Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for P.